Visceral Pain – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Visceral Pain – Pipeline Review, H2 2017’, provides an overview of the Visceral Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Visceral Pain

The report reviews pipeline therapeutics for Visceral Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Visceral Pain therapeutics and enlists all their major and minor projects

The report assesses Visceral Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Visceral Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Visceral Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Anavex Life Sciences Corp

Arena Pharmaceuticals Inc

BELLUS Health Inc

Cadila Healthcare Ltd

Chromocell Corp

Eli Lilly and Company

Grunenthal GmbH

Medestea Research & Production SpA

Pfizer Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Visceral Pain - Overview

Visceral Pain - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Visceral Pain - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Visceral Pain - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Anavex Life Sciences Corp

Arena Pharmaceuticals Inc

BELLUS Health Inc

Cadila Healthcare Ltd

Chromocell Corp

Eli Lilly and Company

Grunenthal GmbH

Medestea Research & Production SpA

Pfizer Inc

Visceral Pain - Drug Profiles

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-1066 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APD-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-5937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-8464 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HS-665 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-656570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBFI-26 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize OXTR for Abdominal Pain and Chronic Visceral Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WITH-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYKR-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Visceral Pain - Dormant Projects

Visceral Pain - Discontinued Products

Visceral Pain - Product Development Milestones

Featured News & Press Releases

Nov 14, 2016: Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Visceral Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Visceral Pain – Pipeline by Addex Therapeutics Ltd, H2 2017

Visceral Pain – Pipeline by Anavex Life Sciences Corp, H2 2017

Visceral Pain – Pipeline by Arena Pharmaceuticals Inc, H2 2017

Visceral Pain – Pipeline by BELLUS Health Inc, H2 2017

Visceral Pain – Pipeline by Cadila Healthcare Ltd, H2 2017

Visceral Pain – Pipeline by Chromocell Corp, H2 2017

Visceral Pain – Pipeline by Eli Lilly and Company, H2 2017

Visceral Pain – Pipeline by Grunenthal GmbH, H2 2017

Visceral Pain – Pipeline by Medestea Research & Production SpA, H2 2017

Visceral Pain – Pipeline by Pfizer Inc, H2 2017

Visceral Pain – Dormant Projects, H2 2017

Visceral Pain – Dormant Projects, H2 2017 (Contd..1), H2 2017

Visceral Pain – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Visceral Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports